Cited by 2,634Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and MetabolismPeroxisome Proliferator-Activated Receptors

Adiponectin and Adiponectin Receptors

Kadowaki, Takashi, Yamauchi, Toshimasa·2005·Endocrine Reviews

Abstract

Metabolic syndrome is thought to result from obesity and obesity-linked insulin resistance. Obesity in adulthood is characterized by adipocyte hypertrophy. Adipose tissue participates in the regulation of energy homeostasis as an important endocrine organ that secretes a number of biologically active "adipokines."Heterozygous peroxisome proliferator-activated receptor-gamma knockout mice were protected from high-fat diet induced obesity, adipocyte hypertrophy, and insulin resistance. Systematic gene profiling analysis of these mice revealed that adiponectin/Acrp30 was overexpressed. Functional analyses including generation of adiponectin transgenic or knockout mice have revealed that adiponectin serves as an insulin-sensitizing adipokine. In fact, obesity-linked down-regulation of adiponectin was a mechanism whereby obesity could cause insulin resistance and diabetes. Recently, we have cloned adiponectin receptors in the skeletal muscle (AdipoR1) and liver (AdipoR2), which appear to comprise a novel cell-surface receptor family. We showed that AdipoR1 and AdipoR2 serve as receptors for globular and full-length adiponectin and mediate increased AMP-activated protein kinase, peroxisome proliferator-activated receptor-alpha ligand activities, and glucose uptake and fatty-acid oxidation by adiponectin. Obesity decreased expression levels of AdipoR1/R2, thereby reducing adiponectin sensitivity, which finally leads to insulin resistance, the so-called "vicious cycle." Most recently, we showed that osmotin, which is a ligand for the yeast homolog of AdipoR (PHO36), activated AMPK via AdipoR in C2C12 myocytes. This may facilitate efficient development of adiponectin receptor agonists. Adiponectin receptor agonists and adiponectin sensitizers should serve as versatile treatment strategies for obesity-linked diseases such as diabetes and metabolic syndrome.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/er.2005-0005

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [25]25. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF 2001 Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid 448 Endocrine Reviews, May 2005, 26(3):439 -451
  2. [55]55. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider Kadowaki and Yamauchi • Adiponectin and Adiponectin Receptors Endocrine Reviews, May 2005, 26(3):439 -451 449

Cited by

Sorted by citations

Authors
Kadowaki, T., & Yamauchi, T.
Affiliations
Japan Science and Technology Agency (JP)
Corresponding author
Kadowaki, Takashi
Venue
Endocrine Reviews
Published
2005-05-01
Volume
26
Issue
3
Pages
439-451
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W1971452427
Cited by
2,634
References
103
Citations by year
2026: 51 · 2025: 67 · 2024: 65 · 2023: 61 · 2022: 62 · 2021: 86 · 2020: 84 · 2019: 90 · 2018: 96 · 2017: 107 · 2016: 127 · 2015: 138 · 2014: 181 · 2013: 204 · 2012: 188
FWCI
19.67
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Kyorin Pharmaceutical
  • Imperial College London
  • Keio University
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Society for the Promotion of Science (10NP0201)
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
adiponectin, adiponectin receptors, AdipoR1, AdipoR2, metabolic syndrome, obesity, insulin resistance, adipokines, adipocyte hypertrophy, AMPK, PPARα, glucose uptake, fatty acid oxidation, osmotin, adiponectin receptor agonist
MeSH terms
Animals, Arteriosclerosis, Disease Models, Animal, Humans, Insulin Resistance, Liver, Models, Molecular, Receptors, Cell Surface, Muscle, Skeletal, Metabolic Syndrome, Intercellular Signaling Peptides and Proteins, Mice, Adiponectin, Receptors, Adiponectin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review